Caris Life Sciences has had a difficult year for shareholders, with the stock down 47.3% over the past 12 months, yet its valuation checks still lean toward the shares looking cheap rather than expensive. With fresh product news in precision oncology and multi cancer screening, the question is whether the market is being too cautious or the valuation score is missing important risks.
- Over the last year, Caris Life Sciences has declined 47.3%, which suggests sentiment around the stock has been weak despite ongoing product developments.
- The commercial rollout of the Caris Detect multi cancer screening test can support higher growth expectations, while execution and adoption risk around new diagnostics may weigh on how much value investors are willing to assign today.
- On Simply Wall St's broader checks, Caris Life Sciences screens as undervalued in 5 of 6 valuation tests, which points to a company that currently leans cheap on the numbers.
The issue now is whether Caris Life Sciences' weak share price performance has already more than accounted for the risks, or if the stock's valuation is still vulnerable to further disappointment.
Find out why Caris Life Sciences' -47.3% return over the last year is lagging behind its peers.
Is Caris Life Sciences a Bargain on Sales?
The P/S ratio is a useful cross check for Caris Life Sciences because revenue is one of the clearer reference points for a business that is still investing heavily in growth. Caris Life Sciences currently trades on a P/S of 5.1x, compared with a biotech industry average of 11.1x and a peer group average of 5.7x.
The tailored fair P/S multiple for Caris Life Sciences, which reflects its sector, margins, scale and risk profile, is 6.4x. That is above the current 5.1x level, which indicates the market is applying a discount relative to what this framework suggests for the stock. Despite the recent launch of the Caris Detect multi cancer screening test, the shares still trade below both the modelled fair ratio and the wider industry benchmark on a simple sales multiple.
On this P/S yardstick, Caris Life Sciences stock appears undervalued relative to what its revenue profile and risk factors would typically imply.
See what the numbers say about this price — find out in our valuation breakdown.
The Caris Life Sciences Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Caris Life Sciences pick up where the valuation checks stop by spelling out which paths for Caris Life Sciences' revenue, margins and future earnings would line up with a higher or lower share price than today, and by setting these out as clear scenarios on the Community page. Instead of just giving a single valuation figure, they unpack the assumptions that sit behind it so you can judge over time whether those assumptions are playing out.
One of the top community narratives on Caris Life Sciences: 78% undervalued
"The market currently prices CAI as a standard diagnostic lab, missing the massive optionality of its 'Data-as-a-Service' business model, where pharmaceutical giants pay to access its treasure trove of patient data for drug discovery..."
Read one of the top narratives on Caris Life Sciences
Do you think there's more to the story for Caris Life Sciences? Head over to our Community to see what others are saying!
The Bottom Line
Caris Life Sciences screens as undervalued on market multiples, with the tailored P/S ratio sitting above where the stock currently trades and broader checks skewing in favor of a discount. That gap only becomes interesting for you if the new diagnostics, including Caris Detect, can scale in a way that supports the revenue and margin profile implied by those benchmarks. The key question is whether today’s lower multiple reflects temporary caution or a fair price for execution and adoption risk in precision oncology and multi cancer screening.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com